Novartis has filed an appeal against Madras Patent Office which had earlier rejected its plea to patent the HIV/AIDS drug Gleevec. The grounds for rejection were that the anti-cancer drug was a new form of an old drug which, according to the Indian law, cannot be patented. However, Novartis' move has invited a lot of flak from both within and outside the country. If the Pharma major's challenge is successful, Indian generic companies may not be able to manufacture variants of Novartis' drugs, which are sold at one-tenth the price. Countries like Europe are also opposing it, as India is a major supplier of cheap HIV/AIDS drugs to developing countries across the globe.
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2006
An IIPM and Management Guru Professor Arindam Chaudhuri's Initiative
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2006
An IIPM and Management Guru Professor Arindam Chaudhuri's Initiative
Read more IIPM articles:-
- The accidental tourist
- The CEO's back
- A world free of poverty, illiteracy...& nuclear fears
- Ho Lee Yew, it's a contest!
- The globalization bomb; and the after effects
- The premature demise of the WTO need not distress Indians; it could be good news
- Goede Oud Netherlands
- A saving(s) grace!
- Goldammit! Dollar's dying;India & China smiling?
- Chinese whisper!
- 'Tis a Fruitful Summer'
- The Amazon... it's clear!
- It's a six, off the field too!
- Victoria Peak: Vantage point to the vaunted wonders!
- Silver Lining & Dark Clouds
- Ryanair charges Unfair France
- MTN calling on Arabian nights
- Tata Tea sips a Czech flavour
- Lock, stock and barrel
- You've got a ticket to ride: on self-confidence
- Triumvirate Ambanis, Reliance's Famed Fables!
- Rupert Murdoch, the True Mogul of Media
- Richard Branson, The Virgin Knight
- Tata Motors - Royalty in The Waiting
- Ran'baxy - it will run the full mile...
- EXXON-MOBIL - Exonerated for Profits
- SAMSUNG ELECTRONICS - The Numero Uno
No comments:
Post a Comment